Tag Archives: BIO Events

Forbes 30 Under 30: Rising Biotech Stars at the 2013 BIO International Convention

Forbes 30 Under 30

For the second year in a row, Forbes magazine published a list of the most awe-inspiring rising stars in science and healthcare – all under the age of 30. A select group of these rising stars will attend the 2013 BIO International Convention and participate in a Keynote Luncheon Tuesday, April 23, with BIO President and CEO Jim Greenwood. Keynotes and evening events are open to Convention Access and Full Convention Access Registrations! Registration discounts Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Show Me the Money: Reimbursement in an ACA World

BIO CEO 2013

A panel at the BIO CEO & Investor Conference focused on reimbursement discussed value from a variety of perspectives and agreed that the landscape is shifting dramatically. The reimbursement roundtable featured payors, providers, and other stakeholders discussing Affordable Care Act (ACA) implementation and the wider reimbursement landscape. With many key provisions of the ACA slated to take effect in 2013 and beyond, the industry is facing sweeping changes to the managed care and reimbursement road map. Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

Tracks & Attendees Put the “International” in the BIO International Convention

BIO International Convention

As the BIO International Convention celebrates its 20th year, there is no time like the present to reflect on the evolution of the world’s largest biotechnology industry gathering, and what it illustrates in terms of the patterns of global industry achievements. Overall attendance growth over the years – from a 4,000-strong audience in 1998 to an audience topping 16,000 in 2012 – provides a clear indication of how far this industry has come towards developing and Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , ,

Word on the Street – Biotech Stocks Only Have Room to Go Up

The Opening Lunch Plenary at this year’s BIO CEO & Investor Conference was a lively discussion between portfolio managers and senior buy-side analysts looking to forecast the year ahead in biotech. BIO’s own, Celia Economides, Director, Investor Relations & Programs, reminded us all where we were 15 years ago at the inception of this event. At the 1999 event, there were 18 presenting companies, zero 1X1 meetings scheduled and 271 attendees.  As of day one, Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

Celgene CEO on New Multiple Myeloma Drug Approvals

BIO CEO

Following on the heels of two big announcements in February, Celgene CEO Robert Hugin (one of FierceBiotech’s most influential people in biopharma) participated in a fireside chat with Joel Sendek, managing director and biotechnology analyst at Stifel Nicolaus & Company, at the 15th Annual BIO CEO & Investor Conference in New York. First, on Friday, February 8, the Food and Drug Administration (FDA) approved Celgene’s drug Pomalyst for patients with multiple myeloma whose disease has Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , , , , , ,